Quantcast

Surveyed U.S. Physicians and Hospital Pharmacy Directors Cite Ofirmev’s Ability to Reduce Postoperative Opioid Use as the Primary Factor Influencing Prescribing and Coverage

April 29, 2014

Use of Emerging Acute Postoperative Pain Treatments Will be Highly Dependent on the Agents’ Formulary Coverage, According to Findings from Decision Resources Group

BURLINGTON, Mass., April 29, 2014 /PRNewswire/ — Decision Resources Group finds that Mallinckrodt’s (formerly Cadence Pharmaceuticals’) Ofirmev, the only parenteral formulation of acetaminophen to have reached the U.S. pain market, enjoys notable use among surveyed surgeons and anesthesiologists, as well as widespread coverage (albeit with restrictions) in the majority of surveyed hospital pharmacy directors’ formularies. Surveyed physicians and hospital pharmacy directors cite the agent’s efficacy in reducing postoperative opioid consumption as the most important attribute driving prescribing and coverage, respectively. Nevertheless, despite their satisfaction with Ofirmev’s opioid-sparing effects, physicians and pharmacy directors continue to report that reducing postoperative opioid consumption and lowering the incidence of opioid-related adverse events remain two of the greatest areas of unmet need in postoperative pain treatment.

http://photos.prnewswire.com/prnvar/20130103/MM36768LOGO

Other key findings from the U.S. Physician & Payer Forum report entitled Acute Moderate to Severe Postoperative Pain: How Will U.S. Prescribers and Payers Determine the Success of Emerging Pain Therapies in the Hospital Setting?:

    --  Anesthesiologists play a significant role in formulary recommendations
        and decisions; thus, this physician type represents an important target
        for drug developers' marketing efforts.
    --  Early-line acute postoperative pain treatment continues to be largely
        dominated by inexpensive, generically-available therapies, in part
        because branded pain therapies are more frequently subject to formulary
        restrictions or are excluded from hospital formularies.
    --  In the hospital setting, pharmacoeconomic data--including cost-efficacy
        analysis and, especially, comparator trials against the current
        standards of care--are critical to securing formulary coverage for
        branded, premium priced postoperative pain therapies.
    --  A new product that reduces patients' length of hospital stay would
        fulfill a critical unmet need in postoperative pain treatment and would
        likely attain hospital formulary inclusion.

Comments from Decision Resources Group Analyst Andrea Buurma:

    --  "Surveyed physicians would welcome new pain therapies, such as Durect's
        Posidur, a long-acting bupivacaine injection, into their postoperative
        pain treatment armamentarium; however, their likelihood to
        prescribe/administer emerging therapies and their expected use of these
        products across select procedures will be largely dependent on formulary
        coverage."
    --  "Perhaps not surprisingly, surveyed hospital pharmacy directors indicate
        that cost is the primary non-efficacy factor that has and will continue
        to drive formulary decisions; formulary inclusion may prove challenging
        if novel pain therapies are priced notably greater than currently
        available agents in their respective drug classes. However, clinical
        trial data that clearly demonstrate cost-benefit advantages such as
        reduction in hospital readmissions for pain, shorter length of stay, or
        reduction in overall costs to the hospital can be leveraged to secure
        more favorable formulary coverage."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort

781-993-2597

ccomfort@dresourcesgroup.com

Photo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group


Source: PR Newswire



comments powered by Disqus